PH12022553502A1 - Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine - Google Patents

Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Info

Publication number
PH12022553502A1
PH12022553502A1 PH1/2022/553502A PH12022553502A PH12022553502A1 PH 12022553502 A1 PH12022553502 A1 PH 12022553502A1 PH 12022553502 A PH12022553502 A PH 12022553502A PH 12022553502 A1 PH12022553502 A1 PH 12022553502A1
Authority
PH
Philippines
Prior art keywords
ylethanamine
pyridin
phenyl
topical formulations
pharmaceutically acceptable
Prior art date
Application number
PH1/2022/553502A
Other languages
English (en)
Inventor
Robert Berman
Charles M Conway
Mary K Donohue
Rajesh Kumar
Ajaya Kumar Reka
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of PH12022553502A1 publication Critical patent/PH12022553502A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
PH1/2022/553502A 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine PH12022553502A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043075P 2020-06-23 2020-06-23
PCT/US2021/038564 WO2021262779A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Publications (1)

Publication Number Publication Date
PH12022553502A1 true PH12022553502A1 (en) 2024-04-22

Family

ID=79281832

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/553502A PH12022553502A1 (en) 2020-06-23 2021-06-23 Topical formulations of (1s)-1-phenyl-2-pyridin-2-ylethanamine

Country Status (12)

Country Link
US (1) US12564579B2 (cg-RX-API-DMAC7.html)
EP (1) EP4168116A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023531918A (cg-RX-API-DMAC7.html)
KR (1) KR20230026449A (cg-RX-API-DMAC7.html)
CN (1) CN115836052A (cg-RX-API-DMAC7.html)
AU (1) AU2021297823A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025900A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187140A1 (cg-RX-API-DMAC7.html)
IL (1) IL299308A (cg-RX-API-DMAC7.html)
MX (1) MX2022016183A (cg-RX-API-DMAC7.html)
PH (1) PH12022553502A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021262779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240350409A1 (en) * 2023-04-20 2024-10-24 LifeActive, Inc. Transdermal delivery formulations and methods for the manufacture thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655840B2 (en) * 1991-07-17 1995-01-12 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
NZ251384A (en) * 1992-04-03 1996-10-28 Fisons Corp (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
KR102336426B1 (ko) 2013-11-05 2021-12-08 아스트라제네카 아베 Nmda 길항제 전구약물
US11358935B2 (en) * 2016-11-28 2022-06-14 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of lanicemine and their method of use
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases

Also Published As

Publication number Publication date
KR20230026449A (ko) 2023-02-24
AU2021297823A1 (en) 2023-02-16
EP4168116A1 (en) 2023-04-26
JP2023531918A (ja) 2023-07-26
EP4168116A4 (en) 2024-07-10
CA3187140A1 (en) 2021-12-30
WO2021262779A1 (en) 2021-12-30
US20230190719A1 (en) 2023-06-22
BR112022025900A2 (pt) 2023-01-10
IL299308A (en) 2023-02-01
MX2022016183A (es) 2023-02-13
US12564579B2 (en) 2026-03-03
CN115836052A (zh) 2023-03-21

Similar Documents

Publication Publication Date Title
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
AU2021311245A8 (en) Compound for androgen receptor degradation, and pharmaceutical use thereof
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
MX2022003845A (es) Tratamientos cognitivos medicinales.
WO2021022058A3 (en) Antiarrhythmic formulation
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MX2026001173A (es) Moduladores del potencial de receptor transitorio melastatina 3 (trpm3) para el tratamiento del dolor
MX2022016183A (es) Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
WO2020170032A3 (en) Method for treatment of rosacea in patients aged 65 years and older
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
MX2023010394A (es) Metodos para tratar el cancer usando una combinacion de regimenes de dosificacion de serd.
WO2021161319A8 (en) Combination therapy for treating amyotrophic lateral using pridopidine and another active agent
IL319025A (en) Methods for treating or preventing endometriosis
ZA202400915B (en) Pharmaceutical composition and use thereof
MX2023009424A (es) Composicion antitranspirante.
MX2018013477A (es) Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.